Building an AI platform to tackle complex diseases

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/91/bf/48/91bf486a-c5a4-9f3e-bef4-85c37a755291/mza_6691556943534461978.jpg/600x600bb.jpg

For People with Purpose by SciPro

SciPro Global

33 episodes

6 days ago

"For People with Purpose by SciPro" is the Life Sciences podcast that brings industry insights and meaningful conversations. Hosted by SciPro’s expert recruitment consultants, each episode features clients from across the Life Sciences sector to discuss key trends, new technologies, and the evolving hiring landscape. Tune in to hear how purpose-driven work is shaping the future of healthcare and life sciences, whether you're a hiring manager, job seeker, or simply passionate about the industry.

Careers

Business

RSS

All content for For People with Purpose by SciPro is the property of SciPro Global and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Careers

Business

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/38968590/38968590-1732876718787-b7860fb01abe6.jpg

Building an AI platform to tackle complex diseases

For People with Purpose by SciPro

31 minutes 42 seconds

11 months ago

Building an AI platform to tackle complex diseases

Nick is joined by Dr.⁠Muhunthan Thillai⁠, the co-founder and CEO of ⁠Qureight⁠ and they discuss the innovative way they are using AI to allow for effective drug development in complex diseases. This is also a fantastic episode for understanding how founders from a medical background have built an AI company.

Dr.Muhunthan Thillai is the co-founder and CEO of Qureight, a medical technology company in Cambridge which aims to pioneer data curation in complex diseases. By structuring image and biomarker data from biopharma and healthcare institutions, Qureight uses their AI-assisted platform to look for new trial endpoints in complex diseases including Idiopathic Pulmonary Fibrosis, Lung Cancer and Pulmonary Hypertension.